Krsnaa Diagnostics Q4 FY26 Results: PAT Rs 42 Cr
- May 26, 2026
- Posted by: Neeraj Pandey
- Category: News
Krsnaa Diagnostics Q4 FY26 results were declared on May 25, 2026. The company reported PAT of Rs 42 crore for the quarter ended March 31, 2026, up 100.0% YoY compared to Rs 21 crore in Q4 FY25. Revenue from operations was Rs 193 crore, up 3.8% YoY. Results are on a Consolidated basis. Krsnaa Diagnostics is a Diagnostics and Radiology company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Krsnaa Diagnostics Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | Rs 193 crore | Rs 186 crore | +3.8% |
| Net Profit | 42 | 21 | +100.0% |
| Basis | Consolidated | ||
Note: Krsnaa Diagnostics Q4 FY26 results declared May 25, 2026. Data sourced from Screener.in BSE filings. Verify from audited statements before investment decisions.
Krsnaa Diagnostics Q4 FY26 Performance Analysis
The Krsnaa Diagnostics Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter shows strong profitability growth of 100% YoY, reflecting improved operational execution. Krsnaa Diagnostics operates in the Diagnostics and Radiology sector, which benefits from India’s GDP growth above 6.5% in FY26.
Revenue of Rs 193 crore was up 3.8% YoY. Stable revenue reflects consistent business delivery.
Screen the best stocks on the Univest Screener.
Key Factors Driving Krsnaa Diagnostics Q4 FY26 Results
Revenue and Business Execution
Revenue of Rs 193 crore in Krsnaa Diagnostics Q4 FY26 was up 3.8% YoY. Stable revenue reflects consistent operational delivery. The January to March quarter is the fiscal year-end period characterised by strong order execution and year-end activity across Indian companies.
Profitability and Margin Trends
The the business PAT of Rs 42 crore up 100.0% YoY. Strong PAT growth demonstrates improving operational leverage and business fundamentals.
India Macro Environment Q4 FY26
India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Reserve Bank of India’s accommodative stance supported credit conditions. The Diagnostics and Radiology sector benefited from these structural tailwinds during the January to March 2026 quarter.
FY27 Outlook
Following the firm results, management guidance on FY27 revenue growth, margin improvement roadmap, and capital allocation priorities will be key investor watchpoints. The Diagnostics and Radiology sector continues to benefit from India’s long-term structural growth story including urbanisation, infrastructure investment, and rising domestic consumption. Sustaining the strong profitability momentum will be the FY27 priority.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Krsnaa Diagnostics Q4 FY26 net profit?
Ans. Krsnaa Diagnostics Q4 FY26 reported PAT of Rs 42 crore, up 100.0% YoY from Rs 21 crore in Q4 FY25. Verify from BSE/NSE audited filings.
What is Krsnaa Diagnostics Q4 FY26 revenue?
Ans. Krsnaa Diagnostics Q4 FY26 revenue was Rs 193 crore, up 3.8% YoY. Verify from BSE/NSE filings.
When were Krsnaa Diagnostics Q4 FY26 results declared?
Ans. Krsnaa Diagnostics Q4 FY26 results were declared on May 25, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.
Is Krsnaa Diagnostics a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is educational only. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
